Flow Cytometry of Hematological Malignancies

Foreword to the First Edition by Maryalice Stetler-Stevenson

Foreword to the First Edition by Bruno Brando

Foreword to the Second Edition by Michael J Borowitz

Preface to the First Edition

Preface to the Second Edition

1 ANTIGENS

• Clustered (CD) Antigens
• CD1 Antigens, XX
• CD2 Antigen, XX
• CD3 Antigen, XX
• CD4 Antigen, XX
• CD5 Antigen, XX
• CD7 Antigen, XX
• CD8 Antigen, XX
• CD10 Antigen, XX
• CD11b Antigen, XX
• CD11c Antigen, XX
• CD13 Antigen, XX
• CD14 Antigen, XX
• CD15 Antigen, XX
• CD16 Antigen, XX
• CD19 Antigen, XX
• CD20 Antigen, XX
• CD22 Antigen, XX
• CD23 Antigen, XX
• CD24 Antigen, XX
• CD25 Antigen, XX
• CD26 Antigen, XX
• CD27 Antigen, XX
• CD28 Antigen, XX
• CD30 Antigen, XX
• CD33 Antigen, XX
• CD34 Antigen, XX
• CD38 Antigen, XX
• CD43 Antigen, XX
• CD45 Antigen, XX
• CD45 Isoforms, XX
• CD48 Antigen, see SLAM molecules, XX
• CD49 Antigens, XX
• CD56 Antigen, XX
• CD57 Antigen, XX
• CD61 Antigen, XX
• CD62L Antigen, XX
• CD64 Antigen, XX
• CD65 Antigen, XX
• CD66c Antigen, XX
• CD71 Antigen, XX
• CD79 Antigen, XX
• CD81 Antigen, XX
• CD84 Antigen, see SLAM molecules, XX
• CD103 Antigen, XX
• CD123 Antigen, XX
• CD117 Antigen, XX
• CD138 Antigen, XX
• CD150 Antigen, see SLAM molecules, XX
• CD158 Antigen, see KIRs, XX
• CD181-186, 191-199 Antigens, see Chemokines and Chemokine Receptors, XX
• CD200 Antigen, XX
• CD229 Antigen, see SLAM molecules, XX
• CD244 Antigen, see SLAM molecules, XX
• CD280-290 Antigens, see Toll-like Receptors, XX
• CD305 Antigen, XX
• CD307 (IRTA) Antigen Family, XX
• CD319 Antigen, see SLAM molecules, XX
• CD352-353 Antigens, see SLAM molecules, XX
• CD371 Antigen, XX
• Non clustered (or primarily known with other names) antigens
• Bcl-2 Protein, XX
• Chemokines and Chemokine Receptors, XX
• CRLF2, XX
• Cytotoxic Proteins, XX
• HLA-DR Antigen, XX
• Immunoglobulins, XX
• KIR, CD158 Isoforms, XX
• Myeloperoxidase (MPO), XX
• NG2 Antigen, XX
• PCA-1 Antigen, XX
• ROR-1 Antigen, XX
• SLAM Molecules and SLAM Associated Protein (SAP), XX
• SOX11, XX
• T-cell Receptor (TCR), XX
• Terminal Deoxy-nucleotidyl Transferase (TdT), XX
• Toll-like Receptors (TLR), XX
• VS38 Antigen, XX
• ZAP-70 Protein, XX 

2 DISEASES

• Myeloproliferative neoplasms, XXX
• Chronic myeloid leukemia (CML), XXX
• Myeloproliferative neoplasms other than CML, XXX
• Chronic neutrophilic leukemia (CNL), XXX
• Polycythemia vera (PV), XXX
• Primary myelofibrosis (PMF), XXX
• Essential thrombocythemia (ET), XXX
• Chronic eosinophilic leukemia (CEL), XXX
• Mastocytosis, XXX
• Acute masT-cell leukemia (AMCL), XXX
• Chronic masT-cell leukemia (CMCL), XXX
• Myelomastocytic leukemia (MML), XXX
• Myelodysplastic/myeloproliferative neoplasms, XXX
• Chronic myelomonocytic leukemia (CMML), XXX
• Other myelodysplastic/myeloproliferative neoplasms and related conditions, XXX
• Juvenile myelomonocytic leukemia (JMML), XXX
• Atypical CML bcr/abl negative (ACML), XXX
• RAS-associated autoimmune leukoproliferative disorder (RALD), XXX
• Myelodysplastic syndromes, XXX
• Myeloid neoplasms with germline predisposition, XXX
• Acute myeloid leukemias, XXX
• AMLs with recurrent genetic anomalies, XXX
• AMLs with chromosomal anomalies, XXX
• AMLs with gene mutations, XXX
• AMLs with recurrent genetic anomalies, not recognized by the WHO
• classification, XXX
• AMLs with myelodysplastic related changes (AML-MRC), XXX
• AMLs not otherwise specified, XXX
• AML with minimal differentiation, XXX
• AML without maturation, XXX
• AML with maturation, XXX
• Acute myelomonocytic leukemia (AMMoL), XXX
• Acute monoblastic or monocytic leukemia (AMoL), XXX
• Pure erythroid leukemia (PEL), XXX
• Acute megakaryoblastic leukemia (AMKL), XXX
• Acute basophilic leukemia (ABL), XXX
• Myeloid proliferations associated with Down syndrome, XXX
• Transient abnormal myelopoiesis (TAM), XXX
• AMLs in patients with Down syndrome, XXX
• Blastic plasmacytoid dendritic cell neoplasm (BPDCN/PDCL), XXX
• Acute leukemias with ambiguous lineage attribution (ALAL), XXX
• Acute undifferentiated leukemias (AUL), XXX
• Mixed phenotype acute leukemias (MPAL), XXX
• Neoplastic diseases of B and T lymphatic precursors, XXX
• B lymphoblastic leukemia/lymphoma,
• not otherwise specified (B-ALL/LBLnos), XXX
• B lymphoblastic leukemia/lymphoma with recurrent genetic anomalies, XXX
• T lymphoblastic leukemia/lymphoma (T-ALL/LBL), XXX
• Early T-cell precursors lymphoblastic leukemia (ETP-ALL), XXX
• NK lymphoblastic leukemia/lymphoma (NK-ALL/LBL), XXX
• Neoplastic diseases of mature B cells, XXX
• Chronic lymphocytic leukemia/small
• lymphocytic lymphoma (B-CLL/SLL), XXX
• Familial B-CLL, XXX
• Richter syndrome, XXX
• Monoclonal B-cell lymphocytosis (MBL), XXX
• B-cell prolymphocytic leukemia (B-PLL), XXX
• Lymphoplasmacytic lymphoma (LPL), XXX
• Heavy chain disease (HCD), XXX
• Gamma heavy chain disease, XXX
• Mu heavy chain disease, XXX
• Alpha heavy chain disease, XXX
• Hairy cell leukemia (HCL), XXX
• Hairy cell leukemia, variant (HCL-v), XXX
• Hairy cell leukemia, Japanese variant (HCL-J), XXX
• Splenic diffuse red pulp lymphoma (SDRPL), XXX
• Marginal zone lymphomas (MZL), XXX
• Nodal marginal zone lymphoma (NMZL), XXX
• Splenic marginal zone lymphoma (SMZL), XXX
• Extranodal marginal zone lymphoma (EMZL/MALToma), XXX
• Clonal B-cell lymphocytosis with MZL-like phenotype (CBL-MZ), XXX
• Follicular lymphoma (FCL), XXX
• Testicular follicular lymphoma, XXX
• Duodenal type follicular lymphoma, XXX
• Pediatric type follicular lymphoma, XXX
• Primitive cutaneous follicular lymphoma (PCFL), XXX
• Large B-cell lymphoma with IRF4 rearrangement, XXX
• Mantle cell lymphoma (MCL), XXX
• Blastic mantle cell lymphoma (BMCL), XXX
• Leukemic non nodal mantle cell lymphoma, XXX
• Diffuse large B-cell lymphomas (DLBCLs), XXX
• DLBCL not otherwise specified (DLBCL nos), XXX
• T-cell/histiocyte-rich B-cell lymphoma (THRLBCL), XXX
• Primary DLBCL of the CNS (PCNSL), XXX
• Primary cutaneous DLBCL, “leg type”, XXX
• EBV(+) DLBCL nos, XXX
• DLBCL associated with chronic inflammation (PAL), XXX
• Lymphomatoid granulomatosis (LyG), XXX
• Primary mediastinal B-cell lymphoma (PMBCL), XXX
• Intravascular large B-cell lymphoma (IVBCL), XXX
• ALK-positive large cell lymphoma (ALK(+) LBCL), XXX
• Plasmablastic lymphoma (PBL), XXX
• Primary effusion lymphoma (PEL), XXX
• HHV8-associated lymphoproliferative disorders, XXX
• Burkitt lymphoma (BL), XXX
• Burkitt leukemia with immature phenotype, XXX
• Burkitt-like lymphoma with 11q aberrations, XXX
• High grade B-cell lymphoma (HGBL), XXX
• Plasma cell neoplasms, XXX
• Monoclonal gammopathies of undetermined significance (MGUS), XXX
• Multiple myeloma (MM), XXX
• Plasma cell leukemia (PCL), XXX
• Neoplastic diseases of mature T and NK cells, XXX
• T-cell prolymphocytic leukemia (T-PLL), XXX
• T-cell large granular lymphocytic leukemia (T-LGL), XXX
• Chronic lymphoproliferative disorders of NK cells (CLPD-NK/CNKL), XXX
• Aggressive NK-cell leukemia (ANKL), XXX
• Adult T-cell leukemia/lymphoma (ATLL), XXX
• Extranodal NK/T-cell lymphoma, “nasal type” (ENKTL), XXX
• Intestinal T-cell lymphoma (ITCL), XXX
• Enteropathy-associated T-cell lymphoma (EATCL), XXX
• Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), XXX
• Indolent gastro-intestinal T lymphoproliferative disorder, XXX
• Hepatosplenic T-cell lymphoma (HTSCL), XXX
• Subcutaneous panniculitis-like T-cell lymphoma (SPTCL), XXX
• Mycosis fungoides (MF), XXX
• Sézary syndrome (SS), XXX
• Primary cutaneous CD30(+) lymphoproliferative disorders, XXX
• Lymphomatoid papulosis (LyP), XXX
• Primary cutaneous anaplastic T-cell lymphoma (cALCL), XXX
• Primary cutaneous peripheral T-cell lymphoma (PTCL), XXX
• Primary cutaneous TCRγδ(+) T-cell lymphoma (PCGD-TCL), XXX
• Primary cutaneous CD8(+) aggressive epidermotropic
• cytotoxic T-cell lymphoma, XXX
• Primary cutaneous acral CD8(+) T-cell lymphoma
• Primary cutaneous lymphoma of the medium/small CD4(+) T cells
• (PCSM-TCL), XXX
• Peripheral T-cell lymphoma, not otherwise specified (PTCLnos), XXX
• Nodal lymphomas of follicular T-helper derivation, XXX
• Angioimmunoblastic T-cell lymphoma (AITL), XXX
• Follicular T-cell lymphoma (FTCL), XXX
• Nodal PTCL with follicular T-helper phenotype, XXX
• Anaplastic large cell lymphoma ALK(+) (ALK(+) ALCL), XXX
• Anaplastic large cell lymphoma ALK(-) (ALK(-) ALCL), XXX
• Breast implant-associated anaplastic large cell lymphoma (biaALCL), XXX
• Neoplastic diseases of histiocytic and dendritic cells, XXX
• Histiocytic sarcoma (HS), XXX
• Langerhans cell histiocytosis (LCH), XXX
• Indeterminate dendritic cell tumor (IDCT), XXX
• Interdigitating dendritic cell sarcoma (IDCS), XXX
• Follicular dendritic cell sarcoma (FDCS), XXX
• Erdheim-Chester disease (EDC), XXX

3 APPENDIX

• Acute leukemias not recognized by the 2016 WHO classification, XXX
• Acute leukemia of myeloid/NK precursors (M/NK-AL), XXX
• Acute leukemia of myeloid dendritic cells (MDCL), XXX
• Acute leukemia of Langerhans cells, XXX
• Mature B-cell lymphoblastic leukemia, XXX
• Composite lymphomas, XXX
• Hypereosinophilic syndrome (HES), lymphocyte variant, XXX
• Indolent T lymphoblastic proliferations (iT-LBP), XXX
• Polyclonal lymphocytoses of B lymphocytes, XXX
• Persistent polyclonal B-cell lymphocytosis (PPBL), XXX
• Persistent polyclonal CD5(+) B-cell lymphocytosis, XXX
• Persistent polyclonal B-cell lymphocytosis, Japanese (hairy) variant, XXX
• Polyclonal plasmacytoses, XXX
• Small round (blue) cell tumors (SR(B)CT), XXX

Index

Flow Cytometry of Hematological Malignancies contains an array of graphical outputs produced by the technique in the study of the most (and the least) common diseases.

Designed to be practical, the book is perfect for quick consultation. This authoritative and state-of-the-art reference will be invaluable for clinicians directly involved in the diagnosis and analysis of hematological diseases, including hematologists, hematopathologists, oncologists, pathologists and technicians working in diagnostic laboratories.